



| | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|--|--|---|-----------|--------------------------|-----------|----------------------------|---------|---------------------------------|--|-------------------|--|---|-----------|--|-----|--|-----------|-------|--|---|--|--|-----------|
| <p>Recipient Information</p> <p>1. Recipient Name CITY & COUNTY OF SAN FRANCISCO 101 GROVE ST SAN FRANCISCO, 94102</p> <p>2. Congressional District of Recipient 12</p> <p>3. Payment System Identifier (ID) 1946000417A8</p> <p>4. Employer Identification Number (EIN) 946000417</p> <p>5. Data Universal Numbering System (DUNS) 103717336</p> <p>6. Recipient's Unique Entity Identifier DCTNHRGU1K75</p> <p>7. Project Director or Principal Investigator William McFarland, MD Professor willi.mcfarland@sfdph.org 415-554-9000</p> <p>8. Authorized Official Willi McFarland willi.mcfarland@sfdph.org 415-554-9016</p> | <p>Federal Award Information</p> <p>11. Award Number 1R01AI169635-01</p> <p>12. Unique Federal Award Identification Number (FAIN) R01AI169635</p> <p>13. Statutory Authority 42 USC 241 42 CFR 52</p> <p>14. Federal Award Project Title Brief Longitudinal Incident Sentinel Surveillance (BLISS) to End the HIV Epidemic among Persons Who Inject Drugs (PWID)</p> <p>15. Assistance Listing Number 93.855</p> <p>16. Assistance Listing Program Title Allergy and Infectious Diseases Research</p> <p>17. Award Action Type New Competing</p> <p>18. Is the Award R&D? Yes</p> | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Federal Agency Information</p> <p>9. Awarding Agency Contact Information Nicole A Guidetti Grants Management Program NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES nicole.guidetti@nih.gov 301-761-6934</p> <p>10. Program Official Contact Information Gerald B. Sharp Program Officer NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES gsharp@niaid.nih.gov 240-627-3217</p> | <p>Summary Federal Award Financial Information</p> <table border="1"> <tr> <td colspan="2">19. Budget Period Start Date 08-15-2022 – End Date 07-31-2023</td> </tr> <tr> <td>20. Total Amount of Federal Funds Obligated by this Action</td> <td style="text-align: right;">\$178,137</td> </tr> <tr> <td> 20 a. Direct Cost Amount</td> <td style="text-align: right;">\$174,774</td> </tr> <tr> <td> 20 b. Indirect Cost Amount</td> <td style="text-align: right;">\$3,363</td> </tr> <tr> <td>21. Authorized Carryover</td> <td></td> </tr> <tr> <td>22. Offset</td> <td></td> </tr> <tr> <td>23. Total Amount of Federal Funds Obligated this budget period</td> <td style="text-align: right;">\$178,137</td> </tr> <tr> <td>24. Total Approved Cost Sharing or Matching, where applicable</td> <td style="text-align: right;">\$0</td> </tr> <tr> <td>25. Total Federal and Non-Federal Approved this Budget Period</td> <td style="text-align: right;">\$178,137</td> </tr> <tr> <td colspan="2">-----</td> </tr> <tr> <td colspan="2">26. Project Period Start Date 08-15-2022 – End Date 07-31-2027</td> </tr> <tr> <td>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</td> <td style="text-align: right;">\$178,137</td> </tr> </table> <p>28. Authorized Treatment of Program Income Additional Costs</p> <p>29. Grants Management Officer - Signature ANNIE NOEL Grimes</p> | 19. Budget Period Start Date 08-15-2022 – End Date 07-31-2023 | | 20. Total Amount of Federal Funds Obligated by this Action | \$178,137 | 20 a. Direct Cost Amount | \$174,774 | 20 b. Indirect Cost Amount | \$3,363 | 21. Authorized Carryover | | 22. Offset | | 23. Total Amount of Federal Funds Obligated this budget period | \$178,137 | 24. Total Approved Cost Sharing or Matching, where applicable | \$0 | 25. Total Federal and Non-Federal Approved this Budget Period | \$178,137 | ----- | | 26. Project Period Start Date 08-15-2022 – End Date 07-31-2027 | | 27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period | \$178,137 |
| 19. Budget Period Start Date 08-15-2022 – End Date 07-31-2023 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 20. Total Amount of Federal Funds Obligated by this Action | \$178,137 | | | | | | | | | | | | | | | | | | | | | | | | |
| 20 a. Direct Cost Amount | \$174,774 | | | | | | | | | | | | | | | | | | | | | | | | |
| 20 b. Indirect Cost Amount | \$3,363 | | | | | | | | | | | | | | | | | | | | | | | | |
| 21. Authorized Carryover | | | | | | | | | | | | | | | | | | | | | | | | | |
| 22. Offset | | | | | | | | | | | | | | | | | | | | | | | | | |
| 23. Total Amount of Federal Funds Obligated this budget period | \$178,137 | | | | | | | | | | | | | | | | | | | | | | | | |
| 24. Total Approved Cost Sharing or Matching, where applicable | \$0 | | | | | | | | | | | | | | | | | | | | | | | | |
| 25. Total Federal and Non-Federal Approved this Budget Period | \$178,137 | | | | | | | | | | | | | | | | | | | | | | | | |
| ----- | | | | | | | | | | | | | | | | | | | | | | | | | |
| 26. Project Period Start Date 08-15-2022 – End Date 07-31-2027 | | | | | | | | | | | | | | | | | | | | | | | | | |
| 27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period | \$178,137 | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>30. Remarks Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise</p> | | | | | | | | | | | | | | | | | | | | | | | | | |

requested from the grant payment system.



RESEARCH
Department of Health and Human Services
National Institutes of Health



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

SECTION I – AWARD DATA – 1R01AI169635-01

Principal Investigator(s):

William McFarland, MD

Award e-mailed to: barbara.garcia@sfdph.org

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$178,137 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI169635. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

ANNIE NOEL Grimes
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

| | |
|--|------------------|
| Federal Direct Costs | \$174,774 |
| Federal F&A Costs | \$3,363 |
| Approved Budget | \$178,137 |
| Total Amount of Federal Funds Authorized (Federal Share) | \$178,137 |
| TOTAL FEDERAL AWARD AMOUNT | \$178,137 |
| | |
| AMOUNT OF THIS ACTION (FEDERAL SHARE) | \$178,137 |

| SUMMARY TOTALS FOR ALL YEARS (for this Document Number) | | |
|---|------------|-------------------|
| YR | THIS AWARD | CUMULATIVE TOTALS |
| 1 | \$178,137 | \$178,137 |
| 2 | \$205,679 | \$205,679 |
| 3 | \$235,470 | \$235,470 |
| 4 | \$235,470 | \$235,470 |
| 5 | \$208,096 | \$208,096 |

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier: 1946000417A8
 Document Number: RAI169635A
 PMS Account Type: P (Subaccount)
 Fiscal Year: 2022

| IC | CAN | 2022 | 2023 | 2024 | 2025 | 2026 |
|----|---------|-----------|-----------|-----------|-----------|-----------|
| AI | 8472297 | \$178,137 | \$205,679 | \$235,470 | \$235,470 | \$208,096 |

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: A27G / OC: 41021 / Released: Grimes, ANNIE 08-01-2022
 Award Processed: 08/15/2022 12:03:52 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R01AI169635-01

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 1R01AI169635-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy

- Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
 - f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of “Research and Development” at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI169635. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

Additional Costs

SECTION IV – AI SPECIFIC AWARD CONDITIONS – 1R01AI169635-01

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

The budget period anniversary start date for future year(s) will be **August 1**.

In accordance with the NIAID Financial Management Plan, NIAID does not provide funds for inflationary increases. See: <https://www.niaid.nih.gov/grants-contracts/financial-management-plan>.

REMINDER: This grant is funded for HIV/AIDS research. Per the NIH Revitalization Act of 1993, funds are restricted for HIV/AIDS research and cannot be re-budgeted for other purposes.

This is a Modular Award without direct cost categorical breakdowns in accordance with the guidelines published in the NIH Grants Policy Statement, see https://grants.nih.gov/grants/policy/nihgps/HTML5/section_13/13.5_post-award_administration.htm. Recipients are required to allocate and account for costs related to this award by category within their institutional accounting system in accordance with applicable cost principles.

This Notice of Award (NoA) includes funds for **Heluna Health**.

This Notice of Award (NoA) includes funds for **University of California San Francisco**.

This Notice of Award (NoA) includes funds for **Alameda County Public Health Department**.

This award includes human subject research studies and must conform to the DHHS policies for the [Protection of Human Subjects](#) research, which are a term and condition of award. Human subjects research is covered by the 2018 Common Rule, and may not be initiated until the associated protocols have received IRB approval as specified in [45 CFR 46](#). Failure to comply with the terms and conditions of award may result in the disallowance of costs and/or additional enforcement actions as outlined in Section 8.5 of the NIH Grants Policy Statement.

SPREADSHEET SUMMARY

AWARD NUMBER: 1R01AI169635-01

INSTITUTION: SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH

| Budget | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|-------------------|-----------|-----------|-----------|-----------|-----------|
| TOTAL FEDERAL DC | \$174,774 | \$202,316 | \$232,107 | \$232,107 | \$204,733 |
| TOTAL FEDERAL F&A | \$3,363 | \$3,363 | \$3,363 | \$3,363 | \$3,363 |
| TOTAL COST | \$178,137 | \$205,679 | \$235,470 | \$235,470 | \$208,096 |

| Facilities and Administrative | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|-------------------------------|--------|--------|--------|--------|--------|
|-------------------------------|--------|--------|--------|--------|--------|

| Costs | | | | | |
|-----------------|----------|----------|----------|----------|----------|
| F&A Cost Rate 1 | 25% | 25% | 25% | 25% | 25% |
| F&A Cost Base 1 | \$13,453 | \$13,453 | \$13,453 | \$13,453 | \$13,453 |
| F&A Costs 1 | \$3,363 | \$3,363 | \$3,363 | \$3,363 | \$3,363 |